IP Library › Granted Patent US 8,003,075
Granted Patent B2
US 8,003,075 · App. 12/763,474 · Granted Aug 23, 2011

Diagnostic assay for human matrix GLA-protein and its use as a biomarker

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,075
App. No.
12/763,474
Granted
Aug 23, 2011
Kind
B2
Abstract

The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample.

Claims (6)

1. A diagnostic kit for assaying human matrix Gla protein in a serum sample, comprising:

one or more monoclonal antibodies directed against an epitope in human matrix Gla protein residues 3-15, 35-49, or 35-53, alone or in combination with a monoclonal antibody directed against an epitope in human matrix Gla protein residues 61-79, or 54-84, or combinations thereof, wherein said one or more antibodies are produced by a hydridoma formed by fusion of cells from a mouse myeloma and spleen cells from a mouse previously immunized with a peptide homologous to human matrix Gla protein residues 3-15, 35-49, 35-53, or 61-79, or 54-84.

2. A monoclonal antibody of class IgG, comprising a monoclonal antibody directed against an epitope in human matrix Gla protein residues 35-53, wherein said antibody is produced by a hydridoma formed by fusion of cells from a mouse myeloma and spleen cells from a mouse previously immunized with a peptide homologous to human matrix Gla protein residues 35-53.

3. A hybridoma cell line B11A#1 deposited with Deutsche Sammlung von Mikroorganizmen and Zellkulturen GmbH (DSMZ) as accession number DSM ACC2639.

4. A hybridoma cell line 52.1#1 deposited with Deutsche Sammlung von Mikroorganizmen and Zellkulturen GmbH (DSMZ) as accession number DSM ACC2638.

5. A monoclonal antibody directed against an epitope in human matrix Gla protein, selected from the group consisting of epitopes in human matrix Gla protein residues 3-15, 35-49, and 35-53.